Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Somerset Therapeutics Private Limited violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

What happens after a Form 483 is issued?

The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.

FDA Form 483 — Somerset Therapeutics Private Limited (February 21, 2025)

FDA inspected Somerset Therapeutics Private Limited in India and issued a Form 483 listing 3 inspectional observations following an inspection that concluded 2025-02-21. FDA records classify Somerset Therapeutics Private Limited as a sterile drug manufacturer. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Somerset Therapeutics Private Limited
FEI / inspection ID	3003821988
Inspection end date	February 21, 2025
Citation count	3

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — Aseptic processing areas are deficient regarding the system for monitoring environmental conditions

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, ......_____,,__ Your viable environmental monitoring (EM) results are not always reliable because the 6 4 (b) (4) plates incubation condition at1b>( ◄>(b><◄> 0 c is not supported by the growth promot ion test (GPT). For example, section 4.10.2 of SOP QCB-091, entitled "Environmental Monitoring Programme fo1( b) (4) Line<b><◄> requires to incubate all E (b) (4) plates a~b><◄>(b><◄> 0c for NL111 b 4 followed by~b>(◄>(b><◄ > 0c forNLT b 4 However, during GPTthe( 6 4 plates are only • ' (I>)(•) ' incubated a1 !b>(◄>!b> 1•> 0 c for s____ You do not have growth promotion data to demonstrate the capability o~(b) (4) media to support microorganism growth a~ > 1◄><b> 1•> 0 c. .

Observation 2 — Batch production and control records do not include complete information relating to

Batch production and control records do not include complete information relating to the production and control of each batch. Specifically, A. There is no assurance that all active air sample data obtained using (b) (4) air samplers are rev iewed and complete as part of the batch production record. Active air samples are obtained throughout the filling area within the filling line (fixed equipment) and the filling area (portable equipment) following QCB-050, "Environmental Monitoring Programme" and QCB-091, "E nvironmental Monitoring Programme for (b) (4) ______ Line!b>l4 >. However, upon review of the electronic data associated with It>><•>of the (b) (4) air samplers, 17 aborted runs were observed, including air samples collected within the (b) (4) areas and corridors. According to your microbiology personnel, these aborted runs are associated with samples which were collected, however the person collecting these samples did not visually ensure that the air sample was completed for the entire b 4 collection time, and these electronic data.

Observation 3 — Laboratory records do not include complete data derived from all tests, examination

Laboratory records do not include complete data derived from all tests, examination and assay necessary to assure compliance with established specifications and standards. Specifically, A. Laboratory results within the LIMS system are not adequately verified to ensure that data obtained from the chromatography system are appropriately reported. For example, the total impurities related to EMPI.O f/S/ SIGNA TVRE EMPLOYEE(S/ NAME AND 1111.E ( or Tn,o/ DATE S ED 02/21/2025 SEE Eileen A. Liu, In vestiga tor (Lead) REVERSE OF Joseph A. Piech ock i, Investigat or TH IS PAGE FORM YDA 483 (1>9/08) l'lUM<lU S EotTION OUSOLE1e INSPECTIONAL OBSERV ATl'ONS PAGB 10 OF ll PAGES

Somerset Therapeutics Private Limited’s FDA history

Argus HQ has recorded 1 total FDA action tied to Somerset Therapeutics Private Limited: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Somerset Therapeutics Private Limited violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
What happens after a Form 483 is issued?: The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Somerset Therapeutics Private Limited

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Form 483 — Somerset Therapeutics Private Limited (February 21, 2025) — 3 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-somerset-therapeutics-private-limited-2025-02-21-3003821988

MLA

"FDA Form 483 — Somerset Therapeutics Private Limited (February 21, 2025) — 3 Citations." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-somerset-therapeutics-private-limited-2025-02-21-3003821988.

Chicago

Argus HQ Research. "FDA Form 483 — Somerset Therapeutics Private Limited (February 21, 2025) — 3 Citations." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-somerset-therapeutics-private-limited-2025-02-21-3003821988.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_somerset_therapeutics_private_limited_2025_02_21_3003821988_2025,
  title = {FDA Form 483 — Somerset Therapeutics Private Limited (February 21, 2025) — 3 Citations},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-somerset-therapeutics-private-limited-2025-02-21-3003821988},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗